Tanshinone IIA pretreatment attenuates ischemia/reperfusion-induced renal injury.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

1. Efficacy and Safety of Sodium Tanshinone IIA Sulfonate Injection on Hypertensive Nephropathy: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019
   Pooled it
2. Exploring Chinese Herbal Medicines for Acute Kidney Injury: Pharmacological Mechanisms and Clinical Potential.Drug design, development and therapy · 2026
   Review
3. Isopropyl 3-(3,4-Dihydroxyphenyl)-2-Hydroxypropanoate Attenuates Experimental Renal Ischemia-Reperfusion Injury by Limiting Sterile Inflammation and Preserving Mitochondrial Function: Involvement of an Nrf2-Associated Cytoprotective Response.Journal of inflammation research · 2026
   Article
4. Plant metabolites: potential treatments for ischemic acute kidney injury.Frontiers in pharmacology · 2026
   Review
5. Pharmacokinetics and brain tissue distribution ofFrontiers in pharmacology · 2025
   Article
6. Renoprotective Effects of Tanshinone IIA: A Literature Review.Molecules (Basel, Switzerland) · 2023
   Review
7. Renoprotective effect of Tanshinone IIA against kidney injury induced by ischemia-reperfusion in obese rats.Aging · 2022
   Article
8. Tanshinone IIA combined with CsA inhibit myocardial cell apoptosis induced by renal ischemia-reperfusion injury in obese rats.BMC complementary medicine and therapies · 2021
   Article
9. Tanshinone IIA Combined With Cyclosporine A Alleviates Lung Apoptosis Induced by Renal Ischemia-Reperfusion in Obese Rats.Frontiers in medicine · 2021
   Article
10. Recent Research Progress (2015-2021) and Perspectives on the Pharmacological Effects and Mechanisms of Tanshinone IIA.Frontiers in pharmacology · 2021
    Review
11. Pharmacokinetics of Active Ingredients of Salvia miltiorrhiza and Carthamus tinctorius in Compatibility in Normal and Cerebral Ischemia Rats: A Comparative Study.European journal of drug metabolism and pharmacokinetics · 2020
    Article
12. Necrostatin-1 Attenuates Renal Ischemia and Reperfusion Injury via Meditation of HIF-1α/mir-26a/TRPC6/PARP1 Signaling.Molecular therapy. Nucleic acids · 2019
    Article
13. Tanshinone IIA promotes osteogenic differentiation of human periodontal ligament stem cells via ERK1/2-dependent Runx2 induction.American journal of translational research · 2019
    Article
14. AMPK activation by Tanshinone IIA protects neuronal cells from oxygen-glucose deprivation.Oncotarget · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as